Overview

Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects

Status:
Completed
Trial end date:
2021-02-02
Target enrollment:
Participant gender:
Summary
The purpose of this clinical study is to assess the safety and tolerability and efficacy of active immunotherapy with dose escalation and cohort expansion of OBI-833 in advanced/metastatic gastric, lung, colorectal, or breast cancer subjects.
Phase:
Phase 1
Details
Lead Sponsor:
OBI Pharma, Inc